Видео с ютуба Mpdac

1st line chemotherapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

Вторая линия химиотерапии при метастатической протоковой аденокарциноме поджелудочной железы (мПАПЖ)

Tackling mPDAC: chemotherapy strategies that matter

Highlights - Tackling mPDAC: chemotherapy strategies that matter

GIANT: chemotherapy regimens in elderly patients with mPDAC

daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC

ARC-8: AB680 + zimberelimab for first-line mPDAC

Real-world safety of second-line 5-FU regimens in mPDAC

ESMO 2020 Highlights on 1st line durvalumab and tremelimumab for mPDAC: The PA.7 study

Phase II trial of elraglusib, a GSK-3ß inhibitor, in untreated mPDAC

NAPOLI 3: UGT1A1*28 Polymorphism and Tolerability in Patients With mPDAC Treated With NALIRIFOX

NOMINATION DES COMMANDANTS SECTEURS DE MPDAC

FOOTPATH: NAPOLI versus sequential NAPOLI and mFOLFOX6 in mPDAC

PANCREAS CANCER ACADEMY 5.0: Quality of Life during mPDAC treatment Utopia or Reality

Second line chemo mPDAC

Dr. Alice Wei on baseline NLRs in predicting clinical outcomes in mPDAC patients

Liposomal irinotecan + fluorouracil/leucovorin after progression in mPDAC

MPDAC - NUESTRAS REDES SOCIALES

ARC-8: Targeting CD73 Inhibition in mPDAC With Quemliclustat and Zimberelimab

Dr. Shahda on BBI-608 With Gemcitabine and Nab-Paclitaxel in Patients with mPDAC